2022
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Mustard C, Kelly J, team H. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e48-e49. PMID: 36456403, DOI: 10.1016/j.eururo.2022.11.006.Peer-Reviewed Original ResearchConceptsIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancerRandomised controlled trialsOpen-labelBladder cancerControlled trialsReply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Kelly J, team H. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e29-e30. PMID: 36272948, DOI: 10.1016/j.eururo.2022.10.009.Peer-Reviewed Original ResearchConceptsIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancerRandomised controlled trialsOpen-labelBladder cancerControlled trialsAdjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Tan W, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly J. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. European Urology 2022, 83: 497-504. PMID: 35999119, DOI: 10.1016/j.eururo.2022.08.003.Peer-Reviewed Original ResearchConceptsIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancerDisease-free survivalAdverse eventsBladder cancerMitomycin CChemotherapy instillationOpen-labelControl armAdjuvant intravesical chemotherapyProgression-free survivalPhase 2 randomised controlled trialIntention-to-treat analysisLow gradePer-protocol analysisChemohyperthermia groupIntravesical chemotherapyUrinary cytologyHeated chemotherapyOverall survivalWeekly instillationsTumor resectionPrimary endpointRandomised controlled trialsChemohyperthermiaAdverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis
Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhasin S, Snyder P, Ellenberg S, Grossmann M, Travison T, Gianatti E, van der Schouw Y, Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic K, Brock G, Tenover J, Tan H, Kong C, Tan W, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Andersen M, Magnussen L, Hernández R, Oliver N, Wu F, Dhillo W, Bhattacharya S, Brazzelli M, Jayasena C. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet Healthy Longevity 2022, 3: e381-e393. PMID: 35711614, PMCID: PMC9184259, DOI: 10.1016/s2666-7568(22)00096-4.Peer-Reviewed Original ResearchConceptsRisk of biasMeta-analysisStudy designSystematic reviewInclusion criteriaCochrane Database of Systematic ReviewsCochrane risk of bias toolDatabase of Systematic ReviewsRisk of bias toolMEDLINE In-Process & Other Non-Indexed CitationsIn-Process & Other Non-Indexed CitationsTwo-stage meta-analysisCharacteristics of interventionsOther Non-Indexed CitationsMeta-analysis of randomised controlled trialsOne-stage meta-analysisFull-text screeningRandomised controlled trialsNon-Indexed CitationsCardiovascular eventsAggregate data meta-analysisCoronary heart diseaseData meta-analysisPeer-reviewed publicationsCochrane Controlled Trials Register
2021
1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. British Journal Of Surgery 2021, 108: znab259.955. DOI: 10.1093/bjs/znab259.955.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerRecurrence-free survivalProgression-free survivalInvasive bladder cancerCarcinoma in situChemo-hyperthermiaAdverse eventsChemotherapy instillationSafety profileBladder cancerBCG groupBCG maintenance therapyTrans-urethral resectionMeta-analysisMonths recurrence rateSystematic reviewComprehensive literature searchQuality of evidenceBCG failureBCG shortageMaintenance therapyOncological outcomesRandomised controlled trialsRecurrence rateEffects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis
Chan V, Tan W, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe J, Wang N, Leow J, Giannarini G, Vasdev N, Shariat S, Enikeev D, Ng C, Teoh J. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis. Cancers 2021, 13: 3274. PMID: 34208888, PMCID: PMC8268689, DOI: 10.3390/cancers13133274.Peer-Reviewed Original ResearchNeoadjuvant hormonal therapyDelayed radical prostatectomyHigh-risk patientsRandomised controlled trialsRadical prostatectomyImmediate RPOncological outcomesCancer-specific survivalIntermediate-risk patientsMeta-analysisNewcastle-Ottawa ScaleDelayed RPIntermediate-riskNon-randomised controlled studiesRisk of biasOverall survivalHormone therapyWatchful waitingExpectant managementActive surveillanceCancer surgeryPathological outcomesNewcastle-OttawaLow riskObservational studyDelayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic
Chan V, Tan W, Leow J, Tan W, Ong W, Chiu P, Gurung P, Pirola G, Orecchia L, Liew M, Lee H, Wang Y, Chen I, Castellani D, Wroclawski M, Mayor N, Sathianathen N, Braga I, Liu Z, Moon D, Tikkinen K, Kamat A, Meng M, Ficarra V, Giannarini G, Teoh J. Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. World Journal Of Urology 2021, 39: 4295-4303. PMID: 34031748, PMCID: PMC8143063, DOI: 10.1007/s00345-021-03734-1.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaLocalised RCCDelayed surgeryCytoreductive nephrectomyDeferred CNOverall survivalCell carcinomaTargeted therapyAssociated with worse cancer-specific survivalAssociated with better overall survivalT1a renal cell carcinomaEffect of delaying surgeryDeferred cytoreductive nephrectomyCancer-specific survivalMeta-analysisElective cancer surgeryNewcastle-Ottawa ScaleSystematic reviewComprehensive literature searchUpfront CNOncological effectivenessRisk of biasImmediate surgeryRandomised controlled trials
2017
PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL
Tan W, Buckley L, Devall A, Loubiére L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths L, Page T, Hodgson D, Datta S, Billingham L, Kelly J. PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL. Journal Of Urology 2017, 197: e367-e368. DOI: 10.1016/j.juro.2017.02.881.Peer-Reviewed Original Research665 Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial
Tan W, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths L, Page T, Hodgson D, Datta S, Bilingham L, Kelly J. 665 Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial. European Urology Open Science 2017, 16: e1156-e1157. DOI: 10.1016/s1569-9056(17)30720-0.Peer-Reviewed Original Research
2016
Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Tan W, Khetrapal P, Tan W, Rodney S, Chau M, Kelly J. Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PLOS ONE 2016, 11: e0166221. PMID: 27820855, PMCID: PMC5098822, DOI: 10.1371/journal.pone.0166221.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyOpen radical cystectomyMeta-analysis of randomised controlled trialsExtracorporeal urinary diversionRandomised controlled trialsRadical cystectomyUrinary diversionPerioperative morbidityBladder cancerLack of Level I evidenceRobot-assisted radical cystectomy groupsPositive lymph node statusOutcomes of robot-assisted radical cystectomySystematic reviewControlled trialsOpen radical cystectomy patientsEfficacy of robot-assisted radical cystectomyInclusion criteriaPositive surgical marginsLymph node statusLymph node yieldMeta-analysisLevel I evidenceIntracorporeal urinary diversionWell-designed trials